QL1706 combined with SOX before and after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have adenocarcinoma (a type of cancer) of the stomach or where the stomach meets the esophagus, at a stage where surgery is possible and the tumor is T3 or higher or has spread to lymph nodes (stage N+).
- You must not have had any prior cancer treatment for this diagnosis, such as chemotherapy, radiation, or surgery.
- You need to be between 18 and 75 years old and be in generally good health (able to do daily activities with little help).
- Your blood counts and organ function (kidney, liver, heart) need to be within certain limits, as checked by tests.
- You must agree to use effective birth control during the study and for 4 months after the last dose.
- You cannot have other serious health issues, like active infections, autoimmune diseases, heart problems, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug QL1706 to standard chemotherapy (SOX) works better than chemotherapy alone for a specific type of stomach cancer. It is given before surgery to shrink the tumor and possibly improve outcomes.
This Phase 2 trial tests whether adding nivolumab to standard chemotherapy (SOX) given before and around surgery can improve outcomes for people with certain stomach or stomach–esophagus junction cancers. It aims to shrink or control the cancer and make surgery more effective.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of three treatments (fruquintinib, sintilimab, and SOX chemotherapy) given before and after surgery for stomach cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This Phase 3 study tests whether adding two medicines (Envollizumab and Fruquintinib) to standard chemotherapy (SOX) works better than SOX alone for people with advanced stomach (gastric) cancer that cannot be surgically removed. It aims to improve how long people live and how well the cancer responds.
This trial tests different adjuvant treatments for patients who had stomach or gastroesophageal junction cancer, received chemotherapy with immunotherapy before surgery, and had a complete response (no cancer left) in the surgical sample. It aims to find which treatment works best to prevent the cancer from coming back.
Hear when a new Gastric Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.